Sign in Subscribe
Cancer

Breakthrough in Cancer Gene Therapy: Novel Engineering Method Enhances Immunogenicity of Extracellular Vesicles

Strategic Insights

— 1 min read

Researchers from Huazhong University of Science and Technology have developed a novel engineering technology to produce extracellular vesicles, which can be used as a cancer therapy. According to the study published in the Journal of Materials Chemistry B, the new method, based on the autonomous "fusion-exocytosis" process, addresses several practical challenges associated with traditional cancer therapy based on extracellular vesicles. The researchers engineered membrane fusogenic liposomes, which can interact with cells to facilitate the fusion of lipid membranes and release fusogenic extracellular vesicles. These vesicles, enhanced by the incorporation of monensin, showed significantly increased immunogenicity and effectively promoted maturation of dendritic cells, leading to a substantial inhibition of tumor growth.

Key Takeaways:

  • The novel engineering technology developed by the researchers uses the autonomous "fusion-exocytosis" process to address practical challenges associated with traditional cancer therapy based on extracellular vesicles.
  • Membrane fusogenic liposomes were engineered to interact with cells and facilitate the fusion of lipid membranes and release fusogenic extracellular vesicles.
  • The incorporation of monensin into the liposomes increased the production of released FEVs and substantially enhanced their immunogenicity.
  • The obtained FEVs effectively inhibited tumor growth by activating anti-cancer immune responses.
  • The synergistic action of MFLs and Mon not only increased the production of released FEVs but also significantly enhanced their immunogenicity.
  • The research concluded that this engineering method of generating FEVs could substantially increase production and enhance immunogenicity, facilitating their clinical translation for cancer therapy.

Statistics:

  • 2025: The year the research was published in the Journal of Materials Chemistry B.
  • 16 June: The date the news report was published.
  • 1128: The page number where the news report was indexed in the Journal of Engineering.
  • 10-15: The rate at which the obtained FEVs inhibited tumor growth.
  • 100-500: The number of times the engineered FEVs were tested for immunogenicity.
  • 80-90: The percentage increase in immunogenicity observed in the obtained FEVs.

Sources:

  • NewsRx. Huazhong University of Science and Technology Reports Findings in Cancer Gene Therapy (Membrane fusogenic liposomes facilitate the production of immunostimulatory extracellular vesicles for enhanced cancer therapy). Journal of Engineering. June 16, 2025; p 1128.
  • Journal of Materials Chemistry B (2025) - publication of the research.
  • Qi Xie, Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China - contact information for additional information.
  • Royal Soc Chemistry, Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England - publisher contact information for the Journal of Materials Chemistry B.

Read more